Hadlima Solution
Product Images NDC 50090-6707

Product Visual Gallery

This gallery contains 68 technical images submitted to the FDA as part of the official labeling for Hadlima (NDC 50090-6707). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Image 01)

A line graph showing the percentage of ACR20 responders over time (in weeks) for a 40 mg every other week dosing of HADLIMA compared to placebo. The graph illustrates a rapid increase and sustained higher response rate with HADLIMA versus a lower, relatively stable response with placebo.*

FDA Label Image

Figure 2 (Image 02)

A line graph depicting percent ASA 20 response over time in weeks comparing Adalimumab (solid line) and placebo (dashed line). The graph shows response trends for groups of 208 and 107 participants respectively, with Adalimumab demonstrating a higher response across the 24-week period.*

FDA Label Image

Samsung Logo (Image 03)

FDA Label Image

Organon Logo (Image 04)

Packaging label panel showing manufacturer information for HADLIMA (adalimumab-bwwd) solution, 40 mg/0.4 mL, manufactured for Organon LLC, a subsidiary of Organon & Co., based in Jersey City, NJ, USA.*

FDA Label Image

Samsung Logo (Image 05)

FDA Label Image

Organon Logo (Image 06)

Packaging label section showing the manufacturer information for HADLIMA (adalimumab-bwwd) 40 mg/0.4 mL solution, subcutaneous use. It states the product is manufactured for Organon LLC, a subsidiary of Organon & Co., based in Jersey City, NJ, USA.*

FDA Label Image

Figure A (Prefilled Syringe)

Illustration labeled 'Figure A' showing a syringe-like device with labeled parts including needle cap, body with window, flange, and plunger. The device appears consistent with a subcutaneous injection syringe.*

FDA Label Image

Refrigerator (Image 08)

The image shows the packaging label for HADLIMA, a human prescription drug containing adalimumab-bwwd. It is presented as a 40 mg/0.4 mL subcutaneous solution supplied by A-S Medication Solutions. The package features the product name and the dosage form prominently.*

FDA Label Image

Light (Image 09)

HADLIMA 40 mg/0.4 mL solution for subcutaneous injection packaging label. The label includes the proprietary name HADLIMA, the generic name adalimumab-bwwd, and indicates the product is a human prescription drug. The labeler is A-S Medication Solutions with NDC 50090-6707.*

FDA Label Image

Caution (Image 10)

The image shows the packaging label for HADLIMA 40 mg/0.4 mL, a subcutaneous solution containing the active ingredient adalimumab-bwwd. The label includes the product name, strength, dosage form, and the labeler, A-S Medication Solutions. The package appears to be a carton or box.*

FDA Label Image

Container (Image 11)

Packaging label of HADLIMA 40 mg/0.4 mL subcutaneous solution by A-S Medication Solutions. The label prominently displays the HADLIMA brand name and dosage strength. It includes instruction text, barcodes, and packaging information typical for prescription drug labeling.*

FDA Label Image

Figure B (Prefilled Syringe)

An instructional illustration labeled Figure B depicting a human hand wearing a wristwatch, positioned next to a syringe. The watch face shows 15 and 30 minute intervals, likely indicating timing guidance related to medication administration.*

FDA Label Image

Figure C (Prefilled Syringe)

An instructional illustration labeled Figure C showing a prefilled syringe, an alcohol swab packet, a red sharps container, and cotton balls or gauze pads. The items appear to be components related to the administration of a subcutaneous injection.*

FDA Label Image

Figure D (Prefilled Syringe)

An instructional illustration showing a hand holding a syringe of HADLIMA 40 mg/0.4 mL solution for subcutaneous injection. The image highlights three checks before use: ensuring the solution is clear, verifying no particles are present, and checking the expiration date.*

FDA Label Image

Figure E (Prefilled Syringe)

An instructional illustration labeled Figure E shows recommended injection sites on a human torso and thighs for subcutaneous administration. It includes advice to clean the skin prior to injection and depicts an alcohol swab packet.*

FDA Label Image

Figure F (Prefilled Syringe)

An instructional illustration labeled Figure F showing two hands holding a syringe. The left hand holds a cap with an arrow indicating removal from the syringe held in the right hand. This image appears to demonstrate how to remove the syringe cap prior to subcutaneous injection.*

FDA Label Image

Figure G (Prefilled Syringe)

An instructional illustration showing the proper subcutaneous injection technique for HADLIMA (adalimumab-bwwd) 40 mg/0.4 mL solution. The image depicts a hand holding a syringe at a 45-degree angle to the skin for injection.*

FDA Label Image

Figure H (Prefilled Syringe)

An instructional illustration labeled Figure H showing hands using a prefilled syringe to administer a subcutaneous injection. The syringe is held above a finger, with an arrow indicating a part of the syringe mechanism being pressed down.*

FDA Label Image

Figure I (Prefilled Syringe)

Illustration showing a hand holding a syringe with the needle retracted after an injection. Instructions indicate proper injection completion by confirming needle retraction and no medicine leakage, with a small drop considered acceptable. A sharps container is depicted nearby for safe disposal.*

FDA Label Image

Samsung Logo (Image 20)

FDA Label Image

Organon Logo (Image 21)

Label section showing the manufacturer information for HADLIMA 40 mg/0.4 mL solution for subcutaneous use, stating it is manufactured for Organon LLC, a subsidiary of Organon & Co., located in Jersey City, NJ, USA.*

FDA Label Image

Figure A (Autoinjector)

An illustration labeled Figure A showing a syringe or pen-like device for subcutaneous injection. It highlights the needle cap at the left end, a base section behind it, a central medicine window to view the liquid, and a medicine label near the right end of the device. No brand or dosage details are shown on the device itself.*

FDA Label Image

Refrigerator (Image 23)

The image shows the packaging label of HADLIMA, a human prescription drug with the active ingredient adalimumab-bwwd. The product is a 40 mg/0.4 mL subcutaneous solution, manufactured by A-S Medication Solutions. The label includes dosage and administration information, storage instructions, and regulatory details.*

FDA Label Image

Light (Image 24)

HADLIMA 40 mg/0.4 mL subcutaneous solution for injection vial. The label includes the proprietary name HADLIMA, the generic name adalimumab-bwwd, the dosage strength 40 mg/0.4 mL, and the labeler A-S Medication Solutions. The vial has a yellow cap and a white and blue printed label.*

FDA Label Image

Caution (Image 25)

HADLIMA 40 mg/0.4 mL subcutaneous solution packaging label. The label includes the proprietary name, generic name adalimumab-bwwd, and is marked for human prescription drug use. The labeler is A-S Medication Solutions. The NDC on the label is 50090-6707.*

FDA Label Image

Container (Image 26)

HADLIMA 40 mg/.4 mL prefilled syringe solution for subcutaneous injection, labeled by A-S Medication Solutions. The label features the proprietary name HADLIMA prominently, indicates the active ingredient is adalimumab-bwwd, and includes dosage form and strength details. The packaging design uses a white background with blue and yellow curved accents.*

FDA Label Image

Figure B (Autoinjector)

An instructional illustration labeled Figure B showing a wrist wearing a pink watch with the time displayed and a close-up of a prefilled injection pen with a visible green dose indicator. This likely demonstrates timing or administration instructions for the HADLIMA subcutaneous solution.*

FDA Label Image

Figure C (Autoinjector)

An instructional illustration showing the components related to the HADLIMA (adalimumab-bwwd) autoinjector. The image includes the autoinjector device, an alcohol swab packet labeled 70% isopropyl, a red sharps container, and cotton balls or gauze. Text notes clarify that alcohol swabs, the sharps container, and cotton balls or gauze are not included in the carton.*

FDA Label Image

Figure D (Autoinjector)

An instructional diagram showing a hand holding a HADLIMA Puncture device. The image highlights checking the syringe for clarity and absence of particles, and verifying the expiration date on the device before use.*

FDA Label Image

Figure E (Autoinjector)

Illustration showing the recommended injection sites for subcutaneous administration of HADLIMA (adalimumab-bwwd) solution, including the abdomen and front thighs. Also depicts an alcohol swab and instruction to clean your skin before injection.*

FDA Label Image

Figure F (Autoinjector)

An instructional illustration showing two hands removing the cap from a prefilled syringe. The syringe is held horizontally, and an arrow indicates the direction to pull the cap off. This image demonstrates a step in preparing an injection using a prefilled syringe, consistent with subcutaneous administration.*

FDA Label Image

Figure G (Autoinjector)

Illustration showing a hand pressing down on the top of a device or vial, with a blue arrow pointing downward and the word "Click" indicating an action step, likely part of an instruction for using HADLIMA (adalimumab-bwwd) 40 mg/0.4 mL subcutaneous solution.*

FDA Label Image

Figure H (Autoinjector)

An instructional illustration labeled Figure H showing a hand gripping the top of a device with the thumb pointing upward, indicating to click. A zoomed inset highlights a rectangular yellow indicator on the device.*

FDA Label Image

Figure I (Autoinjector)

An instructional illustration showing a hand holding a subcutaneous injection pen with a yellow medicine window and a small drop at the needle end. A red sharps container is also depicted. The text indicates checking the yellow medicine window and the absence of leaked medicine to confirm the dose.*

FDA Label Image

Samsung Logo (Image 35)

FDA Label Image

Organon Logo (Image 36)

Label segment showing manufacturing information for HADLIMA (adalimumab-bwwd) injection. It states the product is manufactured for Organon LLC, a subsidiary of Organon & Co., located in Jersey City, NJ, USA.*

FDA Label Image

Figure A (Prefilled Syringe)

An instructional diagram labeled as Figure A illustrating the components of a syringe used for the administration of HADLIMA (adalimumab-bwwd) 40 mg/0.4 mL solution for subcutaneous injection. The diagram identifies the needle cap, the body of the syringe with a window, the flange, and the plunger.*

FDA Label Image

Refrigerator (Image 38)

HADLIMA 40 mg/.4 mL solution for subcutaneous injection packaging label. The label includes the product's proprietary name HADLIMA, the nonproprietary name adalimumab-bwwd, and indicates it is a human prescription drug. The labeler is A-S Medication Solutions, and the product NDC is 50090-6707. The container appears to be a vial with a blue and white label.*

FDA Label Image

Light (Image 39)

The image shows a vial of HADLIMA solution for subcutaneous injection. The vial label indicates the product name HADLIMA, the active ingredient adalimumab-bwwd, and the strength 40 mg per 0.4 mL. The label also includes dosage form and administration route information, and the manufacturer is A-S Medication Solutions.*

FDA Label Image

Caution (Image 40)

HADLIMA 40 mg/0.4 mL solution for subcutaneous injection packaging carton. The label includes the proprietary name HADLIMA, the generic name adalimumab-bwwd, strength 40 mg/0.4 mL, and the labeler A-S Medication Solutions. The package also shows the NDC 50090-6707.*

FDA Label Image

Container (Image 41)

HADLIMA 40 mg/0.4 mL solution for subcutaneous injection vial label by A-S Medication Solutions. The label includes the proprietary name, generic name adalimumab-bwwd, strength, dosage form, route, and product NDC 50090-6707.*

FDA Label Image

Figure B (Prefilled Syringe)

An illustration depicting a wrist wearing a pink watch next to a syringe, shown separately to the right. This instructional figure relates to a subcutaneous injection procedure, possibly indicating timing or steps involved.*

FDA Label Image

Figure C (Prefilled Syringe)

Illustration labeled Figure C depicting a prefilled syringe for subcutaneous injection, an alcohol swab packet, a sharp container box, and cotton balls or gauze pads. The image notes that the alcohol swab, sharp container, and cotton ball or gauze are not included in the carton.*

FDA Label Image

Figure D (Prefilled Syringe)

An instructional illustration labeled Figure D shows a hand holding a syringe filled with solution. The image includes a checklist with three items related to the syringe contents: confirming the solution is clear, ensuring no particles are visible, and verifying the expiration date.*

FDA Label Image

Figure E (Prefilled Syringe)

An instructional illustration labeled "Figure E" showing the torso and upper thighs of a person with a highlighted abdominal injection site. The image includes a depiction of an alcohol swab packet labeled "Alcohol Swab 70% Isopropyl" and the instruction to "Clean your skin" near the injection area, indicating preparation for a subcutaneous injection.*

FDA Label Image

Figure F (Prefilled Syringe)

An illustration showing a pair of hands preparing a syringe by removing a cap from the needle. The image is instructional in nature, demonstrating a step in preparing a subcutaneous injection.*

FDA Label Image

Figure G (Prefilled Syringe)

An instructional illustration showing a subcutaneous injection technique at a 45-degree angle. The image depicts one hand holding the injection site while the other hand inserts a syringe angled at 45 degrees into the skin, demonstrating proper administration guidance for a subcutaneous injection.*

FDA Label Image

Figure H (Prefilled Syringe)

Illustration showing the technique for administering HADLIMA (adalimumab-bwwd) 40 mg/0.4 mL solution via subcutaneous injection. The image depicts a hand holding the syringe with the thumb positioned to push the plunger, indicating the injection process into the skin of the opposite arm.*

FDA Label Image

Figure I (Prefilled Syringe)

An instructional diagram labeled Figure I showing a hand holding a syringe with the needle retracted, hovering above a sharps container. The text advises to ensure the dose is complete when the needle is retracted and no medicine is leaking, indicating proper disposal of the syringe after use.*

FDA Label Image

Samsung Logo (Image 50)

FDA Label Image

Organon Logo (Image 51)

Packaging label showing that the product is manufactured for Organon LLC, a subsidiary of Organon & Co., located in Jersey City, NJ 07302, USA.*

FDA Label Image

Figure A (Autoinjector)

An illustration labeled Figure A depicting a subcutaneous injection pen with labeled parts including needle cap, base, medicine window, and medicine label.*

FDA Label Image

Refrigerator (Image 53)

HADLIMA 40 mg/0.4 mL solution for subcutaneous injection. The label shows the proprietary name HADLIMA prominently, with the nonproprietary name adalimumab-bwwd below it. The label indicates this is a human prescription drug supplied by A-S Medication Solutions, including the product NDC 50090-6707.*

FDA Label Image

Light (Image 54)

HADLIMA 40 mg/.4 mL solution for subcutaneous injection, a human prescription drug containing adalimumab-bwwd. The label shows the proprietary name HADLIMA prominently in blue, with strength and dosage form details. The labeler is A-S Medication Solutions. The image includes instructions and dosage information in smaller text around the label.*

FDA Label Image

Caution (Image 55)

HADLIMA 40 mg/0.4 mL subcutaneous solution branded packaging label. The label displays the product name HADLIMA prominently, active ingredient adalimumab-bwwd, and strength 40 mg/0.4 mL. Labeler is A-S Medication Solutions. The packaging indicates a single-dose injectable solution for human prescription use.*

FDA Label Image

Container (Image 56)

HADLIMA 40 mg/0.4 mL solution for subcutaneous injection packaging label. The label displays the product name and strength, highlighting the active ingredient adalimumab-bwwd. It is labeled as a human prescription drug with a dosage form of solution. The labeler is A-S Medication Solutions, and the product NDC is 50090-6707.*

FDA Label Image

Figure B (Autoinjector)

An instructional illustration labeled "Figure B" showing a wrist wearing a pink watch and a blue and white pen-like injection device, indicating timing or preparation for subcutaneous administration.*

FDA Label Image

Figure C (Autoinjector)

An illustration labeled Figure C showing a HADLIMA (adalimumab-bwwd) autoinjector device. Below it are images of an alcohol swab, a sharps container, and cotton balls or gauze, with a note indicating these items are not included in the carton.*

FDA Label Image

Figure D (Autoinjector)

An instructional illustration showing a hand holding a HADLIMA PushTouch prefilled syringe. The image highlights checking the syringe for no particles and clear solution, and verifying the expiration date on the syringe label before use.*

FDA Label Image

Figure E (Autoinjector)

An instructional illustration labeled 'Figure E' showing common subcutaneous injection sites on a human body, specifically the abdomen and upper thighs. The image also depicts an alcohol swab packet labeled 'Alcohol Swab 70% isopropyl' with a note to clean the skin before injection.*

FDA Label Image

Figure F (Autoinjector)

An instructional diagram labeled Figure F showing two hands holding a pen-like device for subcutaneous injection. One hand is removing the cap from the device by pulling it straight off, indicated by an arrow pointing left. The illustration is likely part of usage instructions for the HADLIMA adalimumab-bwwd solution injection.*

FDA Label Image

Figure G (Autoinjector)

An instructional illustration labeled Figure G depicting a hand holding a pen-like device for subcutaneous injection, poised vertically above an injection site on the skin, with a downward arrow indicating injection direction and the word 'Click' suggesting activation of the device.*

FDA Label Image

Figure H (Autoinjector)

An instructional illustration showing a hand holding a pen-like device vertically, with a close-up detail highlighting an orange indicator labeled to 'Click,' suggesting activation or readiness of the device, likely related to subcutaneous administration.*

FDA Label Image

Figure I (Autoinjector)

Illustration showing a hand holding a prefilled syringe of HADLIMA (adalimumab-bwwd) solution for subcutaneous injection. It highlights the medicine window on the syringe as yellow to indicate a correct dose and notes that a small drop of medicine leakage is acceptable. A sharps container is shown in the background for safe disposal.*

FDA Label Image

Samsung Logo (Image 65)

FDA Label Image

Organon Logo (Image 66)

Packaging label showing the manufacturer information for HADLIMA (adalimumab-bwwd) 40 mg/0.4 mL solution for subcutaneous injection. The label states the product is manufactured for Organon LLC, a subsidiary of Organon & Co., located in Jersey City, NJ 07302, USA.*

FDA Label Image

Figure 3 (Image 72)

Two line graphs labeled Study UV I and Study UV II, showing treatment failure rates (%) over time (months) comparing placebo and HUMIRA. Both graphs depict that treatment failure rate increases over time, with placebo group showing higher failure rates than HUMIRA in each study. The x-axis represents time in months (0 to 20), and the y-axis represents treatment failure rate percentage (0 to 100%). Data points with sample sizes are included below each time point.*

FDA Label Image

Label Image (Lbl500906707)

Packaging label for HADLIMA PushTouch (adalimumab-bwwd) 40 mg/0.4 mL subcutaneous solution by A-S Medication Solutions. The label displays product NDC 50090-6707-0, lot number 7251-0, with directions for storage and usage. It includes a 2 single-dose prefilled autoinjector package with NDC 500900670707.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.